Skip to main content

Yaron Panov and Rochelle Schwartz

Mount Sinai Hospital foundation website

When Yaron Panov had chemotherapy to fight off the same rare type of cancer that has been found in Toronto mayor Rob Ford, the 59-year-old engineer lost his hair and was debilitated by pain, fatigue and nausea.

"I know some people who couldn't get out of bed for a while. Chemotherapy is a treatment that destroys your body, not just your cancer but the good cells as well. So you feel sick. Physically sick," Mr. Panov recalled in an interview.

"Fatigue. Not being able to concentrate. You stay at home and you look at the walls."

Story continues below advertisement

Mr. Panov, a Toronto-area resident, shared his story because it had a happy ending. Despite many travails and expenses, he and his wife, a physician, found a new cancer treatment in the United States that customized his chemotherapy and enabled him to fight back. He is now hoping to bring that new technology to Canada.

He was 55 when he was diagnosed with liposarcoma, an uncommon malignant type of tumour that arises in fatty tissue. Because there are no effective screening strategies for liposarcoma and because it grows in soft tissue, it is often detected late, after it has already grown into a large mass.

Mr. Panov had surgery at the Toronto General Hospital but the cancer came back three months later.

The second time, surgery was no longer an option because the cancer was too spread out. Doctors suggested chemotherapy but the prospects were grim.

"Because it's such a rare recurrence, they didn't have that much experience in Canada with this cancer and that's why I looked for solutions elsewhere," Mr. Panov said.

With his wife, Rochelle Schwartz, he turned to the U.S., where a new technique called Tumorgraft was being developed by the research firm Champions Oncology Inc.

In Tumorgraft, cancerous cells from the patient are implanted and grown on lab mice, then various drugs are tested on them, enabling doctors to find the best pharmaceutical combination.

Story continues below advertisement

Thus, Mr. Panov discovered that the chemotherapy cocktail initially prescribed to him at Mount Sinai Hospital wouldn't have been effective on his tumour while another drug normally used for colorectal cancer would have worked.

"It was working on the mice so I knew it would work on me. It's a boost of morale and confidence ... because I knew it would work."

Taking the guesswork away from chemotherapy is a major benefit because the treatment is so hard on patients, he said.

"Any oncologist you'll ask today, they'll tell you it's an educated, intelligent guess to give you chemotherapy but it's a guess regardless."

Mr. Panov said his successful treatment enabled him to see his two sons graduate from university.

And he is optimistic that he could get even better treatment because newer, more potent drugs are being developed and, thanks to the mice, he wouldn't have to be a guinea pig to see if they're suitable treatment for his type of cancer.

Story continues below advertisement

"It helped me to be very positive, which was easier for me to say `Be positive' because I had something behind me that supported me," he said.

"In the case of Rob Ford, all he has is just his faith, right now. I hope that he has access to this technology as well. I really feel for him, to get such news."

The new treatment didn't come cheap. Mr. Panov and his wife sold their house and moved to a condo.

He hopes to bring Tumorgraft to Canada. The price tag could come down if many patients use it and costs would be offset because it would cut down on redundant chemotherapy, he said.

Mr. Panov and Dr. Schwartz are now working with the Mount Sinai Hospital foundation to raise money to make the treatment, which is also called Precision Chemotherapy, to the Toronto hospital.

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter